Elucid Moves into New Headquarters in Preparation for Commercial Launch
27 Junio 2024 - 6:05AM
Business Wire
Modern Space Allows Room for Growth,
Collaboration and Wellness
Elucid, a pioneering medical technology company providing
physicians with imaging analysis software based on ground truth
histology to support treatment of cardiovascular disease, today
announced it has moved its headquarters to 399 Boylston Street in
the heart of Boston’s Back Bay neighborhood. The move into the
modern space comes as Elucid grows and prepares for
commercialization of its flagship plaque analysis software.
Elucid’s move into the new headquarters follows an $80 million
Series C fundraise in Q4 2023, led by Elevage Medical Technologies,
which was intended to help further commercialization and expansion
plans. As part of its ramp up for commercial launch, which includes
hiring additional employees, Elucid sought out space that would
provide room to grow, encourage collaboration and prioritize
employee wellness.
The new office is centrally located just steps from Boston
Public Garden and in close proximity to multiple public transit
stops. Spanning more than 16,000 square feet, the Boylston Street
headquarters is filled with light and offers a variety of spaces
for collaborative work, and for social gatherings. In addition,
there is a gym area, locker room and bike storage on premise to
encourage fitness.
"This new office space feels like a perfect fit for the Elucid
team,” said Amy Kruglak, vice president of People, Elucid. “This
new environment will foster stronger team connections and enhance
our collaborative efforts, bringing our hybrid workforce together
more effectively to develop and deliver meaningful products that
improve patient care. It also provides the necessary seating and
infrastructure to support our three-year strategic plan."
Cardiovascular disease is the most common cause of death and
disability globally, largely driven by myocardial infarction and
ischemic stroke caused by atherosclerosis (plaque build-up in the
arteries). Elucid offers the first histology-validated FDA-cleared
software to non-invasively quantify and characterize non-calcified
plaque and its components such as lipid-rich necrotic core (LRNC),
giving potential insights into high-risk plaques, key drivers of
risk of heart attack and stroke. The company is also pursuing an
indication for non-invasive measurement of fractional flow reserve
(FFRCT), uniquely derived from its PlaqueIQ technology, to measure
coronary blockages and the extent of ischemia.
About Elucid
Elucid is a Boston-based AI medical technology company dedicated
to developing technology designed to help physicians better
understand the root cause of cardiovascular disease. PlaqueIQ
powers the company’s analysis software, the only FDA-cleared
computed tomography angiography (CTA) algorithm that objectively
quantifies plaque morphology validated against ground truth
histology, the gold standard for characterization of coronary
plaques, as indicated by renowned pathologists. Elucid is also
pursuing an indication for FFRCT, derived from its PlaqueIQ
technology, to help identify coronary blockages and the extent of
ischemia non-invasively. PlaqueIQ equips physicians with critical
information regarding the type and amount of plaque in arteries
that can lead to heart attack and stroke. For more information,
visit elucid.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627036231/en/
Sam Choinski Pazanga Health Communications (860) 301-5058
schoinski@pazangahealth.com